Abeona Therapeutics Inc
abeonatherapeutics.comAbeona Therapeutics Inc (NASDAQ: ABEO) is a clinical-stage biopharmaceutical company focused on developing and commercializing gene therapy products. Revenue is expected to come from commercial product sales, with ZEVASKYN listed as an approved product as of the 10-K filed March 17, 2026, and contingent milestone and royalty payments tied to sub-licensed products under existing license agreements. The company operates in a pre-scale commercial stage, with rights to develop and commercialize product candidates governed in part by licenses granted by third parties, including a license agreement with Ultragenyx Pharmaceutical Inc. dated May 16, 2022. Abeona relies on third-party contract research organizations and manufacturers for clinical development and production, retaining regulatory responsibility for compliance with FDA GMP, GCP, and GLP requirements. CEO Vishwas Seshadri serves as President and Chief Executive Officer, with Joseph Vazzano as Chief Financial Officer, as of March 17, 2026.
Products & Services
ZEVASKYN (approved gene therapy product as referenced in the 10-K filed March 17, 2026). Additional developmental product candidates subject to license agreements, including sub-licensed products with contingent milestone payments tied to development, regulatory, and commercial achievements.
Revenue Model
Product sales from ZEVASKYN and contingent milestone and royalty payments from sub-licensed products under license agreements, as disclosed in the 10-K filed March 17, 2026. Additional capital has been raised through equity issuances and debt financing, including a Loan and Security Agreement with Avenue Venture Opportunities Fund dated January 8, 2024.
Customers & Markets
End markets include patients requiring gene therapy treatments, with reimbursement dependent on third-party payors including Medicare, Medicaid, managed care providers, and private health insurers, as described in the 10-K filed March 17, 2026.
Geographic Exposure
Primary regulatory and commercial focus on the United States, with references to FDA oversight and U.S. third-party payor systems. Foreign regulatory authorities and non-U.S. markets referenced in the context of GMP compliance and OECD pricing models, per the 10-K filed March 17, 2026.
Loading...
